Key Takeaways
- • Bain Capital signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (MTPC) from Mitsubishi Chemical Group in a carve-out transaction valued at approximately 510 billion JPY (3.3 billion USD), according to the firm's announcement dated February 7, 2025.
- • The deal is led by Bain Capital's Private Equity teams in Asia and North America alongside its Life Sciences team, with the company becoming independent upon closing.
- • The transaction is expected to close in the third quarter of 2025, subject to customary closing conditions, regulatory clearance and shareholder approvals.
- • MTPC, founded in 1678 and headquartered in Osaka with more than 5,000 employees, plans to expand internal R&D and pursue licensing, business development and acquisitions under Bain's ownership.
- • Mitsubishi UFJ Morgan Stanley Securities and BofA Securities advised Bain Capital financially, with Morrison Foerster, Mori, Hamada & Matsumoto and Ropes & Gray serving as legal advisors.
Summary
Bain Capital, one of the world's leading private investment firms with approximately $185 billion in assets under management, has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation from Mitsubishi Chemical Group Corporation, the parent of the pharmaceutical unit. The firm announced the transaction on February 7, 2025. The deal values the business at approximately 510 billion yen, or 3.3 billion U.S. dollars, according to Bain's announcement. Other coverage cited a range of figures between $3.3 billion and $3.4 billion, reflecting exchange-rate differences.
The investment is led by Bain Capital's Private Equity teams in Asia and North America together with its Life Sciences team. Masa Suekane, a Partner and Head of Japan Healthcare, Industrials and Financial Services at Bain Capital Private Equity, said the firm would provide its global resources and healthcare team experience to help build a "best-in-class Japanese pharma platform." Ricky Sun, a Partner at Bain Capital Life Sciences, cited government and regulatory initiatives aimed at accelerating the development and approval of innovative medicines in Japan as a source of growth opportunity.
Founded in 1678 and headquartered in Doshomachi, Osaka, MTPC focuses on drug discovery and development in immunology and inflammation, vaccines, central nervous system, diabetes and metabolic disease, and kidney and cancer areas as described in its company profile. The company employs more than 5,000 people globally. As an independent company, MTPC plans to pursue growth through business development, licensing, enhanced R&D productivity, commercialization and strategic acquisitions, with significant investment in both internal product development and external deals.
Bain Capital noted its track record in healthcare, including investments in Aiolos Bio (now part of GSK), Cerevel Therapeutics (now part of AbbVie), Stada and other companies. The firm has more than 70 investment professionals in Japan and has completed over 37 investments there since opening its Tokyo office in 2006.
The transaction is expected to close in the third quarter of 2025. Mitsubishi UFJ Morgan Stanley Securities and BofA Securities are serving as financial advisors to Bain Capital, while Morrison Foerster, Mori, Hamada & Matsumoto and Ropes & Gray are serving as legal advisors.
The investment is led by Bain Capital's Private Equity teams in Asia and North America together with its Life Sciences team. Masa Suekane, a Partner and Head of Japan Healthcare, Industrials and Financial Services at Bain Capital Private Equity, said the firm would provide its global resources and healthcare team experience to help build a "best-in-class Japanese pharma platform." Ricky Sun, a Partner at Bain Capital Life Sciences, cited government and regulatory initiatives aimed at accelerating the development and approval of innovative medicines in Japan as a source of growth opportunity.
Founded in 1678 and headquartered in Doshomachi, Osaka, MTPC focuses on drug discovery and development in immunology and inflammation, vaccines, central nervous system, diabetes and metabolic disease, and kidney and cancer areas as described in its company profile. The company employs more than 5,000 people globally. As an independent company, MTPC plans to pursue growth through business development, licensing, enhanced R&D productivity, commercialization and strategic acquisitions, with significant investment in both internal product development and external deals.
Bain Capital noted its track record in healthcare, including investments in Aiolos Bio (now part of GSK), Cerevel Therapeutics (now part of AbbVie), Stada and other companies. The firm has more than 70 investment professionals in Japan and has completed over 37 investments there since opening its Tokyo office in 2006.
The transaction is expected to close in the third quarter of 2025. Mitsubishi UFJ Morgan Stanley Securities and BofA Securities are serving as financial advisors to Bain Capital, while Morrison Foerster, Mori, Hamada & Matsumoto and Ropes & Gray are serving as legal advisors.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.